Phase 4 N=210 Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™
Hepatitis B · Hepatitis A
Primary: Anti-HAV Antibody Concentrations — 360.5; 257.2; 450.8; 335.6 mIU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,175 A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR)-24 (Scheduled Treatment Period) — 37.7; 42.9; 43.5; 40.7 Percentage of patients — p=0.584
Phase 4 N=217 Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)
Allergies
Primary: Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet. — 150; 39; 28 Participants — p=<0.0001
Phase 4 N=261 Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)
Perennial Allergic Rhinitis
Primary: Mean Maximum Plasma Concentration (Cmax) of SCH 29851 (Unchanged Drug; Loratadine), SCH 34117 (Active Metabolite), and SCH 45581 (3OH-SCH 34117) — 3.04; 5.54; 6.48; 4.16…
Phase 4 N=593 Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
Smoking Cessation
Primary: Number of Participants With 4-week Continuous Abstinence — 209; 37 participants — p=<0.0001
Phase 4 N=83 Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder
Bipolar Disorder
Primary: Pittsburgh Sleep Quality Index (PSQI) Global Score — 10.17; 10.88; 8.16; 9.28 units on scale
Phase 4 N=293 Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin A1c) — -1.303 percentage (%) of total haemoglobin — p=<0.0001
Phase 4 N=207 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
Type 2 Diabetes · Hypertension
Primary: Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment — -19.9 mm Hg…
Phase 4 N=241 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
Opiate Dependence · Drug Dependence
Primary: Response Rate — 83.2; 88.7 Percentage of participants
Phase 4 N=537 Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
Depressive Disorder, Major
Primary: Number of Patients Responding "Very Satisfied" on Satisfaction With Depression Care Scale (SDCS) — 160; 138 participants — p=0.218
Phase 4 N=1 Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX
Hemophilia B
Primary: Number of Participants Reporting Efficacy
Phase 4 N=214 Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
Pulmonary Disease, Chronic Obstructive
Primary: Mean Number of Exacerbations Per Year: Negative Binomial Model — 0.864; 0.862 Number of exacerbations per year — p=0.73
Phase 4 N=530 A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia
Fibromyalgia
Primary: Patient's Global Impressions of Improvement (PGI-I) at Week 12 — 2.79; 3.36 units on a scale — p=<0.001
Phase 4 N=45 Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
ADHD NOS
Primary: ADHD-Clinical Global Impression — 29 subjects
Phase 4 N=125 Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline Computer-based Continuous Performance Test (cb- CPT; Qbtech AB, Sweden), Variable: Hyperactivity (Includes Time Active [TA], Distance [DIS], Area…